Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This study is being performed to prospectively determine whether dacarbazine plus Genasense is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit of normal). LDH is a biomarker strongly associated with improved outcomes in a recent trial of dacarbazine plus Genasense.
Epistemonikos ID: 87331d5a01d95dbcc9d73f706e326adc7273f5d2
First added on: May 04, 2024